News / Taiwan / cnyes
Taiho's Antithrombotic Oral Film BEQIA Enters FDA NDA Review Phase
Health Technology · Pharmaceuticals: Major · cnyes · 2026-08-24
6467
Taiho announced that its antithrombotic oral film drug BEQIA has officially entered the FDA's substantive NDA review process, with global licensing efforts underway.
What Happened
Review Status: Taiho (6467-TW) has officially confirmed that its antithrombotic oral film drug, BEQIA (TAH3311), has entered the substantive review phase for its New Drug Application (NDA) with the U.S. FDA. The application was formally accepted on June 22, and the company received no notice of incomplete filing by the August 21 deadline, signaling the start of the formal review process.
Drug Technology: BEQIA utilizes Taiho's proprietary TDS transdermal and transmucosal drug delivery platform. This technology is designed to improve patient compliance and drug absorption efficiency, serving as a cornerstone of the company's pharmaceutical innovation strategy.
Global Strategy: In parallel with the FDA review, Taiho is actively advancing global licensing and partnership opportunities for BEQIA. The company aims to leverage these international collaborations to accelerate the commercialization of its innovative drug delivery platform on a global scale.
Future Outlook: Taiho remains committed to navigating the regulatory requirements as the FDA review progresses. This milestone serves as a critical step in the company's development, strengthening its position in international licensing negotiations and paving the way for future market entry.